1236199-60-2 Usage
Uses
Used in Pharmaceutical Industry:
7-(5-(1,5-dichloropentan-3-yl)-1-Methyl-1H-benzo[d]iMidazol-2-yl)-N-hydroxyheptanaMide is used as a pharmaceutical agent for its potential therapeutic effects. Its unique molecular structure allows it to interact with specific biological targets, making it a promising candidate for the development of new drugs.
Used in Chemical Research:
7-(5-(1,5-dichloropentan-3-yl)-1-Methyl-1H-benzo[d]iMidazol-2-yl)-N-hydroxyheptanaMide is also used in chemical research as a starting material or intermediate for the synthesis of other complex organic molecules. Its unique structure and functional groups make it a valuable tool for exploring new chemical reactions and developing novel synthetic routes.
Used in Material Science:
7-(5-(1,5-dichloropentan-3-yl)-1-Methyl-1H-benzo[d]iMidazol-2-yl)-N-hydroxyheptanaMide can be utilized in material science for the development of new materials with specific properties. Its unique molecular structure and functional groups can be exploited to create materials with tailored characteristics for various applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1236199-60-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,3,6,1,9 and 9 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1236199-60:
(9*1)+(8*2)+(7*3)+(6*6)+(5*1)+(4*9)+(3*9)+(2*6)+(1*0)=162
162 % 10 = 2
So 1236199-60-2 is a valid CAS Registry Number.
1236199-60-2Relevant academic research and scientific papers
[1-methyl-2 - (7 the [...] - [...] ) - 5-N, N-b (2 the [...] -chloro ethyl] - 1H-benzimidazole synthetic method
-
, (2017/04/25)
The invention discloses a synthetic method of [1-methyl-2-(8'-octyl hydroxamic acid group)-5-N,N-bi(2'-chloroethyl)]-1H-benzimidazole. NL-101, namely [1-methyl-2-(8'-octyl hydroxamic acid group)-5-N,N-bi(2'-chloroethyl)]-1H-benzimidazole is prepared from
HYDROXAMIC ACID DERIVATIVES
-
Page/Page column 42, (2010/08/08)
The disclosure includes hydroxamic compounds of Formula I: (I) wherein P, Z, and m are defined herein. Also disclosed is a method for treating a neoplastic disease or an immune disease with these compounds.
